Medical News Today: What to know about mouth sores from chemo

People can get temporary mouth sores from chemotherapy. Checking the mouth often helps early detection, while keeping the mouth moist and avoiding certain foods can help relieve symptoms. Learn more here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Related Links:

CONCLUSION: Due to its unclear components, potential toxicities, misuse, and over-application, TCM might contribute to tumorigenesis and progression of head neck carcinoma. We seek effective approaches to ensure the safe use of TCM. PMID: 31424693 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
This study investigated whether photobiomodulation (PBM) can potentiate the effects of cisplatin on keratinocytes (HaCat) and cancer cells (SCC25 and HN12).Cells were treated with laser (GaAlAs; 660nm; 60mW; 0.33J; 2.14W/cm2; 11.7J/cm2 and 6s) and cisplatin (7.8 µg/mL) to evaluate cell viability,Ki‐67, VEGF, TGF‐β1, EGF expression, and ROS production. Observations were validated in the SCC25 cell lineage, where the type of cell death (necrosis/apoptosis) and the amount of ATP were assessed. Cell lineages showed increased sensitivity to cisplatin assoc iated with PBM (Cis‐PBM). Ki‐67 was augmented in all ...
Source: Photochemistry and Photobiology - Category: Science Authors: Tags: Research Article Source Type: research
CONCLUSIONS: Low-dose DOAC reduces the rate of overall VTE in higher-risk cancer patients starting systemic chemotherapy. It may reduce the rate of symptomatic VTE but increase the likelihood of bleeding. This article is protected by copyright. All rights reserved. PMID: 31420937 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: J Thromb Haemost Source Type: research
Authors: Inoue M, Kusumoto H, Shiono H, Shintani Y, Ose N, Sakamaki Y, Okami J, Higashiyama M, Takeuchi Y Abstract Feasibility is one of the major concerns during adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. A phase II clinical trial of adjuvant chemotherapy with four courses of carboplatin (AUC 5 at day 1) and S-1 (80 mg/m2/day for 2 weeks followed by a 2-week rest) was performed to evaluate the feasibility (UMIN 9101). The primary endpoint was the completion rate and the secondary endpoints were adverse events, 2-year overall survival and disease-free rates....
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
Source: Clinical Nutrition - Category: Nutrition Authors: Tags: Nutrition and cancer II Source Type: research
Source: Clinical Nutrition - Category: Nutrition Authors: Tags: Oral Communication IV: Nutritional Assessment Intervention and Outcome I Source Type: research
In this study, the role of EVs in mediating the response of oral squamous cell carcinoma (OSCC) cells to cisplatin was investigated. We isolated and characterized EVs from OSCC cell lines showing differential sensitivities to cisplatin. Increased EV production was observed in both de novo (H314) and adaptive (H103/cisD2) resistant lines compared to sensitive H103 cells. The protein profiles of these EVs were then analyzed. Differences in the proteome of EVs secreted by H103 and H103/cisD2 indicated that adaptation to cisplatin treatment caused significant changes in the secreted nanovesicles. Intriguingly, both resistant H...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractThe aim of our study is to investigate the efficacy of metronomic cyclophosphamide plus low dose of corticosteroids in advanced or metastatic castration-resistant prostate cancer (CRPC) before, between, and after standard chemotherapy, such as docetaxel and cabazitaxel, and new hormonal treatments, such as abiraterone and enzalutamide. A retrospective analysis was performed on 37 patients. Cyclophosphamide was given orally 50  mg per day together with low dose of corticosteroids, namely dexametasone orally 1 mg per day or prednisone 10 mg per day. Seventeen patients (51%) showed a PSA decline≥&thi...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
This study evaluated the pharmacokinetics and safety of i.v. NEPA in cancer patients. This was a single-center, single-dose phase 1 study in patients receiving highly emetogenic chemotherapy. Patients received a 30-min infusion of i.v. NEPA plus oral dexamethasone (12 mg) prior to chemotherapy, and oral dexamethasone (8 mg/daily) on days 2-4. Twenty-four patients received the complete i.v. NEPA infusion volume. Fosnetupitant maximum plasma concentration (Cmax) was reached at the end of infusion and decreased to
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Sci Source Type: research
CONCLUSION: The rates of the different skin toxicities peaked at various times and were improved at the end of follow-up. Nevertheless, their clinical management could be optimized with a better adherence to current recommendations. The impact of skin toxicities on patient's quality of life appeared to be limited. PMID: 31413534 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Learning | Oral Cancer | Universities & Medical Training